| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/20/2001 | CA2534186A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2534018A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2533831A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2403420A1 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | CA2403397A1 Methods and compositions for rna interference |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403220A1 Methods and compositions for the regulation of vasoconstriction |
| 09/20/2001 | CA2403205A1 Compositions and methods of regulated protein expression in gut endocrine k cells |
| 09/20/2001 | CA2403201A1 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 09/20/2001 | CA2403196A1 Method and composition for treating airway hyperresponsiveness |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2402948A1 Use of growth hormone in low dose |
| 09/20/2001 | CA2402908A1 Assay for agents that induce chemokinesis |
| 09/20/2001 | CA2402877A1 Ifi206, a novel interferon-induced polypeptide, and nucleic acids encoding the same |
| 09/20/2001 | CA2402855A1 Transcription transactivator protein |
| 09/20/2001 | CA2402846A1 Treatment of rosacea |
| 09/20/2001 | CA2402772A1 Apolipoprotein-a-i regulation of t-cell signalling |
| 09/20/2001 | CA2402733A1 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 09/20/2001 | CA2402729A1 Human immune response proteins |
| 09/20/2001 | CA2402721A1 Derivatives of breast cancer antigen her-2 for therapeutical use |
| 09/20/2001 | CA2402639A1 L-leucyl-l-leucine methyl ester treatment of donor lypmhocyte infusions in hematopoietic stem cell transplant patients |
| 09/20/2001 | CA2402614A1 Insulin homolog polypeptide zins4 |
| 09/20/2001 | CA2402413A1 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | CA2402327A1 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | CA2402248A1 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | CA2402086A1 Self antigen vaccines for treating b cell lymphomas and other cancers |
| 09/20/2001 | CA2402041A1 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | CA2402014A1 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | CA2401873A1 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | CA2401448A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2401406A1 Human olfactory receptors and genes encoding same |
| 09/20/2001 | CA2401273A1 Il-17 receptor like molecules and uses thereof |
| 09/20/2001 | CA2400238A1 Human nim1 kinase |
| 09/20/2001 | CA2373237A1 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 09/19/2001 | EP1134286A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/19/2001 | EP1134230A1 Novel polypeptide |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133995A2 Interleukin-1 inhibitors |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133993A1 Substances for the treatment of spinal muscular atrophy |
| 09/19/2001 | EP1133988A1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/19/2001 | EP1133979A2 Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon |
| 09/19/2001 | EP1133692A1 Methods of identifying viral therapeutics |
| 09/19/2001 | EP1133575A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 09/19/2001 | EP1133572A2 Chlamydia pneumoniae genome sequence |
| 09/19/2001 | EP1133571A1 Methods and compositions for pain management |
| 09/19/2001 | EP1133567A1 Methioninase gene therapy for tumor treatment |
| 09/19/2001 | EP1133563A2 Methods and molecules relating to cd39-like polypeptides |
| 09/19/2001 | EP1133560A1 Human parathyroid hormone modifications, preparation and use |
| 09/19/2001 | EP1133557A2 Growth factor modulators |
| 09/19/2001 | EP1133555A2 Pharmaceutical factor vii preparation |
| 09/19/2001 | EP1133552A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| 09/19/2001 | EP1133522A1 Antagonistic analogs of gh-rh inhibiting igf-i and -ii |
| 09/19/2001 | EP1133521A1 The cxc chemokine h174 and methods for preventing damage to the nervous system |
| 09/19/2001 | EP1133520A2 Compositions and methods using lactadherin or variants thereof |
| 09/19/2001 | EP1133519A2 Functional antagonists of hedgehog activity |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133516A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 09/19/2001 | EP1133317A1 Transport system conjugate |
| 09/19/2001 | EP1133315A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 09/19/2001 | EP1133314A1 Method of treating sickle cell disease and thalassemia |
| 09/19/2001 | EP1133313A2 Calcitonin for the modulation of sperm function |
| 09/19/2001 | EP1133312A2 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
| 09/19/2001 | EP1133311A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 09/19/2001 | EP1133310A2 Artery- and vein-specific proteins and uses therefor |
| 09/19/2001 | EP1133309A1 A method of treatment |
| 09/19/2001 | EP1133308A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 09/19/2001 | EP1133307A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| 09/19/2001 | EP1133285A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 09/19/2001 | EP1133284A1 New process |
| 09/19/2001 | EP1133281A1 Dispersible phospholipid stabilized microparticles |
| 09/19/2001 | EP0948522A4 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |
| 09/19/2001 | EP0918536B1 Composition comprising insulin and insulin-like growth factor-i (igf-i) |
| 09/19/2001 | EP0910389A4 Method of promoting bone growth with hyaluronic acid and growth factors |
| 09/19/2001 | EP0889901B1 Process and intermediates for the synthesis of lhrh antagonists |
| 09/19/2001 | EP0866804B1 Cosmetic preparations containing vertebrate proteins and having antibacterial, antimycotical and antiviral action |
| 09/19/2001 | EP0862634B1 Pharmaceutical composition for treating papillomavirus tumours and infection |
| 09/19/2001 | EP0802986B1 Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods |
| 09/19/2001 | EP0789584B1 Application of superoxide dismutase in liposomes |
| 09/19/2001 | EP0772630B1 Streptogramine derivatives, preparation of same and pharmaceutical compositions containing same |
| 09/19/2001 | EP0754751B1 Novel deoxyribonuclease |
| 09/19/2001 | EP0700302B1 Device for treating diabetes mellitus |
| 09/19/2001 | EP0700300B1 Purification of plasma proteins |
| 09/19/2001 | EP0692984B1 Systemic effects of nitric oxide inhalation |
| 09/19/2001 | EP0640099B1 Peptides having tachykinin antagonist activity |
| 09/19/2001 | EP0603406B1 Fowl mycoplasma antigen, gene thereof, recombinant vector containing said gene, and vaccine prepared by utilizing the same |
| 09/19/2001 | EP0600062B1 Polymer-bound paclitaxel derivatives |
| 09/19/2001 | EP0593755B1 Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment |
| 09/19/2001 | CN1313951A Assay to indicate the presence of non-fertilisable ova |
| 09/19/2001 | CN1313903A Compound and method for the prevention and/or the treatment of allergy |
| 09/19/2001 | CN1313897A New gene of humanlysoenzyme, the encoding polypeptide and methods for preparing them |
| 09/19/2001 | CN1313895A Useful properties of a bee venom protein and gene encoding same |
| 09/19/2001 | CN1313866A Method for chromatographically purifying insulins |
| 09/19/2001 | CN1313863A Inhibitors of urokinase and blood vessel fomation |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313846A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases |
| 09/19/2001 | CN1313774A Vaccine comprising cytokine-induced heat shock proteins |
| 09/19/2001 | CN1313773A Antigenic peptides derived from telomerase |
| 09/19/2001 | CN1313772A Peptide antagonists of zonulin and methods for use of same |
| 09/19/2001 | CN1313401A Polypeptide-human space I enzyme 11 and polynucleotide for coding it |